Apilimod dimesylate - LAM Therapeutics

Drug Profile

Apilimod dimesylate - LAM Therapeutics

Alternative Names: LAM 002A; LAM-002

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LAM Therapeutics
  • Class Antirheumatics; Hydrazines; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma
  • Preclinical Neurological disorders

Most Recent Events

  • 30 Nov 2017 LAM Therapeutics enters into a collaboration with Genentech for atezolizumab to be used in combination with apilimod
  • 30 Nov 2017 Phase-II clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO)
  • 30 Nov 2017 Phase-II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, Monotherapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top